New EU Project to Develop a Novel Pandemic Influenza Vaccine

EUInternational experts in the field of human virus research and vaccine development have teamed up to develop a pandemic influenza vaccine. The aim of the EU-funded FluVac project is to conduct research and development (R&D) into a novel pandemic influenza vaccine that could be used as a potential emergency vaccination. The project partners, recently awarded a grant of €3.5 million under the EU's Sixth Framework Programme (FP6), plan to deliver a prototype vaccine within four years.

The emergence of the highly pathogenic strain of avian flu (H5N1) in South East Asia was accompanied by concerns about a potential pandemic influenza outbreak. Prevention and control in such a scenario would depend on the availability of large quantities of a highly effective vaccine at short notice.

"In the event of an influenza pandemic, vaccination will play a key role in its control. Therefore, availability of a sufficient number of vaccine doses will be critical. In this project, we will exploit the potency of the adjuvant [a substance added to a vaccine to increase the body's immune response to it] to potentiate immunity and to reduce the antigen dose required per vaccination," explains Dr Luuk Hilgers, the scientific coordinator of the project at Nobilon International.

As combining a powerful new adjuvant with a novel H5N1 vaccine has produced encouraging results, the project will now move on to developing the vaccine in phase I and II clinical trials. These are expected to take place within two years.

If the trials are successful, the consortium will then carry out further clinical development, and eventually market the vaccine.

"At the end of the project, we expect to have a prototype (concept) flu vaccine with proven efficacy and safety in humans, ready for further development to control an influenza pandemic," Dr Hilgers explained.

The European Commission has funded many research projects targeting influenza, providing funding of over €90 million since 2001. Such research will continue under FP7, and the Commission recently announced the first projects in this area that will receive funding under FP7. Of 44 influenza-related proposals received by the Commission, 11 have been pre-selected for funding. The projects selected are set to receive some €27 million between them, and address issues such as diagnostics, drug and vaccine development and capacity building.

For further information, please visit:
http://ec.europa.eu/food/animal/diseases/controlmeasures/avian/index_en.htm

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...